Uncategorized

UnitedHealth, Elevance and some BCBS plans have deleted senior leadership pages from their corporate sites, while Centene and CVS scrubbed images of their executives online.

The program has recently become controversial as a number of high-profile advanced approvals were granted only for the drugs to fail a confirmatory trial later on. Now, the FDA has clearly laid out expectations.

It’s the latest provider to be hit with a hefty settlement. Earlier this year, Novant Health and Cerebral paid $6.6 million and more than $7 million, respectively, to settle similar claims.

Brian Thompson’s death on Wednesday set off a flood of darkly celebratory social media posts offset by solemn remembrances from his peers and other healthcare leaders.

Embecta said its patch pump would require additions to be commercially competitive, and plans to use the funds saved to pay down debt.

It is not clear what specifically the new facility will produce, though Amgen could be ramping up its manufacturing capacity as it prepares to enter the obesity space with MariTide.

Protara is advancing a cell therapy that triggers both adaptive and innate antitumor immune responses, while CG Oncology’s approach makes use of an oncolytic immunotherapy that preferentially targets cancer cells and proliferates inside them, destroying them from the inside.

Eli Lilly is aggressively ramping up its manufacturing capacity for tirzepatide as compounding pharmacies continue to challenge an FDA decision to formally end the shortage of the obesity and diabetes drug.

  Plinko es un juego que ha ganado una popularidad indiscutible en las plataformas de casino en línea. Con su simplicidad y potencial para generar grandes premios, se ha convertido en un clásico que atrae tanto a jugadores novatos como a expertos. En este artículo, explo …

Not developing potency assays and gaining knowledge about MOAs early in the drug development process not only can break ATMP success but can cause costs and delays that lead to company closures.